Fish Oil Supplementation Reduces Cachexia and Tumor Growth While Improving Renal Function in Tumor-Bearing Rats
详细信息 查看全文
- 作者：Isabela Coelho (1)
Fernando Casare (1)
Danielle C. T. Pequito (1)
Gina Borghetti (1)
Ricardo K. Yamazaki (1)
Gleisson A. P. Brito (1)
Marcelo Kryczyk (1)
Luiz Claudio Fernandes (1)
Terezila M. Coimbra (2)
Ricardo Fernandez (1) ricfer@ufpr.br - 关键词：Fish oil supplementation – ; Fatty acid – ; Renal function – ; Cachexia – ; Glomerular filtration – ; Sodium excretion
- 刊名：Lipids
- 出版年：2012
- 出版时间：November 2012
- 年：2012
- 卷：47
- 期：11
- 页码：1031-1041
- 全文大小：534.2 KB
- 参考文献：1. Aguila MB, Pinheiro AR, Aquino JC, Gomes AP, Mandarim–De–Lacerda CA (2005) Different edible oil beneficial effects (canola oil, fish oil, palm oil, olive oil, and soybean oil) on spontaneously hypertensive rat glomerular enlargement and glomeruli number. Prostaglandins Other Lipid Mediat 76:74–85
2. An WS, Kim HJ, Cho K, Vaziri ND (2009) Omega–3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol 297:F895–F903
3. Baggio B, Budakovic A, Priante G, Gambaro G, Manzato E, Khan S (2002) Dietary fatty acid supplementation modulates the urinary excretion of calcium and oxalate in the rat. Insight into calcium lithogenesis. Nephron 91:486–491
4. Bayorh MA, Williams EF, Ogbolu EC, Walker CE, Manor EL, Brown LG, Chenault VM (1996) Effects of MaxEPA on salt-induced hypertension: relationship to [3H]nitrobenzylthioinosine binding sites. Clin Exp Hypertens 18:37–49
5. Blackburn GL, Maini BS, Bistrian BR, Mcdermmott WV Jr (1977) The effect of cancer on nitrogen, electrolyte and mineral metabolism. Cancer Res 37:2348–2353
6. Boer WH, Fransen R, Shirley DG, Walter SJ, Boer P, Koomans HA (1995) Evaluation of lithium clearance method: direct analysis of tubular lithium handling by micropuncture. Kidney Int 47:1023–1030
7. Brown SA, Brown CA, Crowell WA, Barsanti JA, Kang C, Allen T, Cowell C, Finco DR (2000) Effects of dietary polyunsaturated fatty acid supplementation in early renal insufficiency in dogs. J Lab Clin Med 135:275–286
8. Calder PC (2006) Polyunsaturated fatty acids and inflammation. Prostaglandins Other Lipid Mediat 75:197–202
9. C芒mara NO, Martins JO, Landgraf RG, Jancar S (2009) Emerging roles for eicosanoids in renal diseases. Curr Opin Nephrol Hypertens 18:21–27
10. Caygill CPJ, Charlett A, Hill MJ (1996) Fat, fish, fish oil and cancer. Br J Cancer 74:159–164
11. Coimbra TM, Janssen U, Gr枚ne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57:167–182
12. Culp BR, Titus BG, Lands WE (1979) Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med 3:269–278
13. De Caterina R, Endres S, Kristensen SD, Schmidt EB (1994) N–3 fatty acids and renal diseases. Am J Kidney Dis 24:397–415
14. Diaz Encarnacion MM, Warner GM, Cheng J, Gray CE, Nath KA, Grande JP (2011) N-3 Fatty acids block TNF-α-stimulated MCP-1 expression in rat mesangial cells. J Physiol Renal Physiol 300:1142–1151
15. DiBona GF (1986) Prostaglandins and nonsteroidal anti-inflammatory drugs. Effects on renal hemodynamics. Am J Med 17:12–21
16. Dolegowska B, Pikuła E, Safranow K, Olszewska M, Jakubowska K, Chlubek D, Gutowski P (2006) Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion: the effect of alprostadil. Prostaglandins Other Lipid Mediat 75:403–411
17. Donadio JV, Grande JP (2004) The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 24:225–243
18. Donadio JV (2001) N-3 Fatty acids and their role in nephrologic practice. Curr Opin Nephrol Hypertens 10:639–642
19. Dusing R, Struck A, G枚bel BO, Weisser B, Vetter H (1990) Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 38:315–319
20. Evans WJ, Morley JE, Argil茅s J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: a new definition. Clin Nutr 27:793–799
21. Fassett RG, Gobe GC, Peake JM, Coombes JS (2010) Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis 56:728–742
22. Fearon KCH, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD (2006) Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24:3401–3407
23. Fernandes LC, Carpinelli AR, Hell NS, Curi R (1991) Improvement of cancer cachexia and decrease of Walker 256 tumor growth by insulin administration in rats. Cancer Ther Control 1:259–268
24. Fernandez R, Piechnik J, Fabris R, Malnic G, Fernandes LC (2004) Effect of chronic fish oil supplementation on renal function of normal and cachectic rats. Braz J Med Biol Res 37:1481–1489
25. Francescato HDC, Marin ECS, Cunha FQ, Costa RS, Silva CGA, Coimbra TM (2011) Role of endogenous hydrogen sulfide on renal damage induced by adriamycin injection. Arch Toxicol 85:1597–1606
26. Friedman A, Moe S (2006) Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol 1:182–192
27. Fuehr J, Kaczmarczyk J, Kruttgen CD (1955) A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics. Klin Wochenschr 33:729–730
28. Giacosa A, Frascio F, Sukkar SG, Roncella S (1996) Food intake and body composition in cancer cachexia. Nutrition 12:S20–S23
29. Grossberg AJ, Scarlett JM, Marks DL (2010) Hypothalamic mechanisms in cachexia. Physiol Behav 100:478–489
30. Hao C, Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71:1105–1115
31. Hao C, Breyer MD (2008) Physiological regulation of prostaglandins in the kidney. Ann Rev Physiol 70:357–377
32. Jiang WG, Bryce RP, Horrobin DF (1998) Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol 27:179–209
33. Kim G (2008) Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press 6:35–41
34. Lauretani F, Semba RD, Bardinelli S, Miler ER, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L (2008) Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 54:475–481
35. Logan JL, Michael UF, Benson B (1992) Dietary fish oil interferes with renal arachidonic acid metabolism in rats: correlations with renal physiology. Metabolism 41:382–389
36. Luft FC (2007) Cachexia has only one meaning. J Mol Med 85:783–785
37. Morrison AR (1986) Biochemistry and pharmacology of renal arachidonic acid metabolism. Am J Med 80:3–11
38. Mund RC, Pizato N, Bonatto S, Nunes EA, Vicenzi T, Tanhoffer R, de Oliveira HH, Curi R, Calder PC, Fernandes LC (2007) Decreased tumor growth in Walker 256 tumor-bearing rats chronically supplemented with fish oil involves COX-2 and PGE2 reduction associated with apoptosis and increased peroxidation. Prostaglandins Other Lipid Mediat 76:113–120
39. Munger K, Baylis C (1988) Sex differences in renal hemodynamics in rats. Am J Physiol 254:223–231
40. Pandalai PK, Pilat MJ, Yamazaki K (1996) The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 16:815–820
41. Peake J, Gobe G, Fassett R, Coombes J (2011) The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats. Mol Nutr Food Res 55:400–410
42. Pinto JA Jr, Folador A, Bonato SJ, Aikawa J, Yamazaki RK, Pizato N, Facin M, Grohs H, de Oliveira HH, Naliwaiko K, Ferraz AC, Nishiyama A, Fernandez R, Curi R, Fernandes LC (2004) Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats. J Nutr Biochem 15:358–365
43. Raymond C, Harris Jr, Matthew D, Breyer BM (2008) Arachidonic Acid Metabolites and the Kidney. In: The Kidney, chap. 11
44. Remuzzi G, Bertani T (1998) Pathophysiology of progressive nephropathies. N Engl J Med 339:1448–1456
45. Rettori O, Vieira-Matos AN, Gontijo JR (2000) Re-assessment of the renal hydrosaline dysfunction in rats bearing the Walker-256 tumor. Ren Fail 22:769–784
46. Ruxton CHS, Reed SC, Simpson MJA, Millington KL (2004) The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 17:449–459
47. Schlondorff D (1995) The role of chemokines in the initiation and progression of renal disease. Kidney Int 47:S44–S47
48. Schmitz PG, O’donnell MP, Kasiske BL, Keane WF (1991) Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. J Lab Clin Med 18:129–135
49. Shapiro H, Theilla M, Attal-Singer J, Singer P (2011) Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol 7:110–121
50. Simopoulos AP (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 233:674–688
51. Smith H, Finkelstein N, Aliminosa L, Crawford B, Graber M (1945) The renal clearances of substituted hippuric acid derivates and other aromatic acids in dog and man. J Clin Invest 24:388–404
52. Svendsen KB, Bech JN, S酶rensen TB, Pedersen EB (2000) A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, rennin, vasopressin and urinary excretion of albumin and α-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 56:383–388
53. Thomsen K, Nielsen CB, Flyvbjerg A (2002) Effects of glycine on glomerular filtration rate and segmental tubular handling of sodium in conscious rats. Clin Exp Pharmacol Physiol 29:449–454
54. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89:381–410
55. Toal JN, Millar FK, Brooks RH, White J (1961) Sodium retention by rats bearing the Walker carcinosarcoma 256. Am J Physiol 200:175–181
56. Togni V, Ota CC, Folador A, J煤nior OT, Aikawa J, Yamazaki RK, Freitas FA, Longo R, Martins EF, Calder PC, Curi R, Fernandes LC (2003) Cancer cachexia and tumor growth reduction in walker 256 tumor-bearing rats supplemented with n-3 polyunsaturated fatty acids for one generation. Nutr Cancer 46:52–58
57. Usalan C, Emry S (1998) Membranoproliferative glomerulonephritis associated with small cell lung carcinoma. Int Urol Nephrol 30:209–213
58. Zipser RD (1985) Effects of selective inhibition of thromboxane synthesis on renal function in humans. Am J Physiol 248:753–756
59. Zoja C, Abbate M, Remuzzi G (2006) Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens 15:250–257 - 作者单位：1. Departamento de Fisiologia, Setor de Ci锚ncias Biol贸gicas, Universidade Federal do Paran谩 (UFPR) Centro Polit茅cnico s/n.鈥揓d. das Am茅ricas, Post Box 19031, Curitiba, PR 81531-990, Brazil2. Departamento de Fisiologia鈥揊aculdade de Medicina de Ribeir茫o Preto, Universidade de S茫o Paulo (USP), Ribeir茫o Preto, SP, Brazil
- ISSN：1558-9307
文摘
The objective of the present work was to study the renal function of healthy and tumor-bearing rats chronically supplemented with fish oil (FO), a source of n-3 polyunsaturated fatty acids. Weanling male rats were divided in two groups, one control (C) and another orally supplemented for 70 days with FO (1 g/kg body weight). After this time, half the animals of each group were injected in the right flank with a suspension of Walker 256 tumor cells (W and WFO). The W group had less proteinemia reflecting cachectic proteolysis, FO reversed this fact. Tumor weight gain was also reduced in WFO. Glomerular filtration rate (GFR) was not different in FO or W compared to C, but was higher in WFO. Renal plasma flow (RPF) was higher in the FO supplemented groups. The W group had lower plasma osmolality than the C group, but FO supplementation resulted in normalization of this parameter. Fractional sodium excretion (FENa+) of FO rats was similar to C. Proximal Na+ reabsorption, evaluated by lithium clearance, was similar among the groups. Urinary thromboxane B2 (TXB2) excretion was lower in the supplemented groups. The number of macrophages in renal tissue was higher in W compared to C rats, but was lower in WFO rats compared to W rats. In conclusion, FO supplementation resulted in less tumor growth and cachexia, and appeared to be renoprotective, as suggested by higher RPF and GFR.